1. Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P

Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33: 667-8, 2015.  [Letter] 

 doi: 10.1200/JCO.2014.59.4614 PMID: 25605839.

 

2. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P

Frequency of TERT promoter mutations in human cancers. Nature communications 4: 2185, 2013.  [Article] 

 doi: 10.1038/ncomms3185 PMID: 23887589.

 

3. Melo M, Costa G, Ribeiro C, Carrilho F, Martins MJ, da Rocha AG, Sobrinho-Simões M, Carvalheiro M, Soares P

Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. The Journal of clinical endocrinology and metabolism 98: 4364-72, 2013.  [Article] 

 doi: 10.1210/jc.2013-2267 PMID: 24037891.

 

4. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of clinical endocrinology and metabolism 99: E754-65, 2014.  [Article] 

 doi: 10.1210/jc.2013-3734 PMID: 24476079.

 

5. Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. The Journal of clinical endocrinology and metabolism 102: 1898-1907, 2017.  [Article] 

 doi: 10.1210/jc.2016-2785 PMID: 28323937.

 

6. Tavares C, Eloy C, Melo M, Gaspar da Rocha A, Pestana A, Batista R, Bueno Ferreira L, Rios E, Sobrinho Simões M, Soares P

mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. International journal of molecular sciences 19: ., 2018.  [Article] 

 doi: 10.3390/ijms19051448 PMID: 29757257.

 

7. Tavares C, Coelho MJ, Eloy C, Melo M, da Rocha AG, Pestana A, Batista R, Ferreira LB, Rios E, Selmi-Ruby S, Cavadas B, Pereira L, Sobrinho Simões M, Soares P

NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocrine connections 7: 78-90, 2018.  [Article] 

 doi: 10.1530/EC-17-0302 PMID: 29298843.

 

8. Gerhard R, Teixeira S, Gaspar da Rocha A, Schmitt F

Thyroid fine-needle aspiration cytology: Is there a place to virtual cytology? Diagnostic cytopathology 41: 793-8, 2013.  [Article] 

 doi: 10.1002/dc.22958 PMID: 23441010.

 

9. Soares P, Celestino R, Gaspar da Rocha A, Sobrinho-Simões M

Papillary Thyroid Microcarcinoma: How to Diagnose and Manage this Epidemic? International journal of surgical pathology 22: 113-9, 2014.  [Article] 

 doi: 10.1177/1066896913517394 PMID: 24401191.

 

10. Melo M, Vicente N, Ventura M, da Rocha AG, Soares P, Carrilho F

The role of ablative treatment in differentiated thyroid cancer management Expert Review of Endocrinology & Metabolism 12: 109-116, 2017.  [Review] 

 doi: 10.1080/17446651.2017.1289839.